Managed by Gilead Sciences, Inc. • Latest filing Q4 2025
Overlap peers will appear here as data populates
Related fund suggestions coming soon.
| $515.4M |
| 6.72M |
| 0.00% |
| — |
| 6 | G | $467.6M | 16.71M | 0.00% | — |
| 7 | G | $461.7M | 16.71M | 0.00% | — |
| 8 | R RCUS — | $447.6M | 30.06M | 0.00% | — |
| 9 | A ACLX — | $442.6M | 6.72M | 0.00% | — |
| 10 | A ACLX — | $440.9M | 6.72M | 0.00% | — |
| 11 | A ACLX — | $438.2M | 6.72M | 0.00% | — |
| 12 | R RCUS — | $427.4M | 31.42M | 0.00% | — |
| 13 | G | $419.4M | 16.71M | 0.00% | — |
| 14 | R RCUS — | $255.8M | 31.42M | 0.00% | — |
| 15 | R RCUS — | $246.7M | 31.42M | 0.00% | — |
| 16 | A ASH — | $153.2M | 4.51M | 0.00% | — |
| 17 | A ASH — | $115.3M | 4.51M | 0.00% | — |
| 18 | L LPG — | $42.6M | 452.5K | 0.00% | — |
| 19 | T TNGX — | $40.8M | 4.85M | 0.00% | — |
| 20 | A ASH — | $40M | 2.21M | 0.00% | — |